Iteos Therapeutics Inc - Asset Resilience Ratio
Iteos Therapeutics Inc (ITOS) has an Asset Resilience Ratio of 49.37% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Iteos Therapeutics Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Iteos Therapeutics Inc's Asset Resilience Ratio has changed over time. See Iteos Therapeutics Inc book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Iteos Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Iteos Therapeutics Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $307.61 Million | 49.37% |
| Total Liquid Assets | $307.61 Million | 49.37% |
Asset Resilience Insights
- Very High Liquidity: Iteos Therapeutics Inc maintains exceptional liquid asset reserves at 49.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Iteos Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Iteos Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Iteos Therapeutics Inc (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Iteos Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 51.31% | $352.52 Million | $686.98 Million | +9.26pp |
| 2023-12-31 | 42.05% | $280.74 Million | $667.59 Million | -1.44pp |
| 2022-12-31 | 43.49% | $328.36 Million | $754.99 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $884.71 Million | -- |
About Iteos Therapeutics Inc
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lym… Read more